Scancell reports Phase 2 data showing strongly improved outcomes in Late-Stage Melanoma with its Immunobody iSCIB1+
July 22, 2025 02:00 ET Â | Source: Scancell Holdings Plc SCOPE trial…
Medidata and the University of Sydney’s NHMRC Clinical Trials Centre Broaden Efforts to Revolutionize Clinical Studies in Australia
Continuing collaboration will utilize the capabilities of the Medidata Data Experience, fostering…
Bonerge Initiates Clinical Trial on Urolithin A and Fisetin for Sleep & Wellbeing
NEW YORK--(BUSINESS WIRE)--In 2025, Bonerge initiated a clinical trial (Registration #NCT06990256) investigating…
Veeda Lifesciences announces partnership with Mango Sciences to bring AI innovation in clinical trials services
AHMEDABAD, India, July 8, 2025 /PRNewswire/ -- Veeda Lifesciences, a global contract…
Apogee Therapeutics to Host Conference Call to Report Part A 16-Week Data from the Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe Atopic Dermatitis on July 7, 2025
SAN FRANCISCO and BOSTON, July 06, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics,…
Green Crypto Revolution: Ripplecoin Mining Unveils Global AI-Powered Sustainable Cloud Mining with Free Trial
The new platform eliminates the participation barrier, integrates AI intelligence and green…
AB Science: Masitinib receives FDA and EMA authorization for confirmatory phase 3 trial in metastatic castrate-resistant prostate cancer
PRESS RELEASE MASITINIB RECEIVES FDA AND EMA AUTHORIZATION FOR CONFIRMATORY PHASE 3…
Novotech Earns Frost & Sullivan’s 2025 Global Company of the Year Recognition for Excellence in Biotech Clinical Research Services
Recognized for its biotech-first focus, innovation in clinical trial delivery, and best-in-class…
Instil Bio Announces U.S. F.D.A. Clearance of Investigational New Drug (IND) Application for AXN-2510, a PD-L1xVEGF Bispecific Antibody, for a Phase 1 Trial in Relapsed/Refractory Solid Tumors
July 02, 2025 06:00 ET Â | Source: Instil Bio US phase 1…
Belite Bio Announces Completion of Enrollment in the Pivotal Global Phase 3 PHOENIX Trial Evaluating Oral Tinlarebant in Geographic Atrophy
July 02, 2025 03:00 ET Â | Source: Belite Bio, Inc -Â 500…